Q2 2025 Flerie AB Earnings Call Transcript
Key Points
- Flerie AB (STU:1NP1) has strengthened its position as a top-tier European investment company with significant assets totaling SEK4.1 billion.
- The company has a diverse and mature portfolio, with 93% of its fair value in clinical and commercial stages.
- Flerie AB (STU:1NP1) successfully executed a share-for-share merger with Toleranzia, eliminating transaction fees and allowing Toleranzia to raise funds privately.
- The company has outperformed both the NASDAQ Biotechnology Index and the Swedish Investment Company Index over the past year.
- Flerie AB (STU:1NP1) has managed its cash effectively, maintaining a neutral cash position for the quarter despite significant investments and divestments.
- The deployment rate of investments is currently lower than the company's historical aim, at around 8% of net asset value.
- Nanologica, a listed company in the portfolio, experienced a slight negative share price development, decreasing the segment's fair value by SEK5 million.
- The redemption program showed a participation rate of 4.73%, indicating some shareholders may not have been fully engaged or aware of the opportunity.
- The company faces challenges in the current macroeconomic environment, with high interest rates typically impacting biotechnology investments negatively.
- Flerie AB (STU:1NP1) had to trigger a mandatory bid for Nanologica shares, which was not initially intended, indicating potential regulatory complexities in managing large shareholdings.
Welcome to the Q2 report from Flerie. I welcome you from all your different locations, around the world and Sweden from your holiday locations. Thank you for joining. And for those of you who are Swedish speakers, perhaps you have the chance to see the interview with the Doggins in the industry, television, this morning as well.
So let us get right into it. We of course have the usual disclaimer that I hope you will all follow, and today we're talking about not only the Q2 report, but the fact that it is in fact an anniversary of our IPO. We have done a lot. We have much to show. It is the 27, June was our one year anniversary exactly going onto the main market after the reverse merger that we did on earlier that month in June 2024.
And there has been a lot of portfolio progress and also some financial innovation, I think that we would like to share with you something quite unique that some of you have asked us about and we're happy to answer questions on any details you are curious about.
Let's go straight into the current net
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
